# Building a TTO in a medical college or hospital

URL: https://zernyxhub.com/blog/tto-medical-college
Author: Dr. Abhay Tharmatt, Research Scientist, R&D, Zernyx Innovations
Published: 2026-11-12
Category: Technology transfer

> Medical college IPR cell setup: the policy, committee, disclosure and MTA rules a hospital TTO needs, with AIIMS and ICMR examples and a first-year budget.

**Short answer:** A medical college IPR cell or TTO needs an IP policy, a committee to decide filings, a disclosure route for clinicians, and rules for material transfer and patient data. AIIMS's IPR Policy 2017 is a working model: IP from staff research vests in AIIMS, a committee chaired by the Dean (Research) decides, and inventors receive 70% of licensing income.

A surgeon modifies a retractor because the standard one slips. A microbiologist develops a faster culture method for a resistant infection. A radiologist's team writes software that flags a pattern on scans. In a medical college, inventions arrive from the ward as often as from the lab, and the people making them are usually too busy with patients to think about patents until a company asks.

A technology transfer office (TTO) or IPR cell catches these inventions before they are lost. This guide covers what a medical college needs in place, using AIIMS's policy and ICMR's guidelines as working examples, and a first-year plan.

## What does a medical college TTO need?

| Element | Purpose | AIIMS example |
|---|---|---|
| IP policy | Who owns what, and how income is shared | IPR Policy 2017 |
| Decision committee | Decides filings, funding and licences | IP Management Committee, chaired by the Dean (Research) |
| Operating unit | Handles disclosures, filings, licensees | IPR & Technology Transfer Division |
| Disclosure route | How clinicians report inventions | Disclose to the Division before grant applications or industry contact |
| Material and data rules | Controls what leaves the institute | MTA for research materials; data protection agreement for sensitive personal data |
| Dispute route | Settles disagreements | Director's decision is final |

Source: [AIIMS IPR Policy 2017](https://www.aiims.edu/aiims/departments_17_5_16/IPR/01-IPR%20policy%202017-for%20upload.pdf). [University IP policy](https://zernyxhub.com/blog/university-ip-policy) covers the general structure of an institutional policy.

## Who owns the inventions?

AIIMS's policy vests IP from research by its faculty, scientists, students, project staff and visitors in AIIMS, with or without intramural support. It carves out:

| Situation | Rule in AIIMS's policy |
|---|---|
| Scholarly works | Authors keep copyright; AIIMS gets a free non-exclusive licence for teaching and research |
| Sponsored research | A written agreement with the sponsor governs ownership; without one, AIIMS owns the IP |
| Collaborative work | Jointly owned, in shares based on intellectual input |
| Students | Can be co-inventors; AIIMS owns the IP |

Any medical college writing its own policy should decide each of these in advance. Where hospitals take sponsored research from device and pharma companies, the sponsor's contract will claim results if the policy is silent.

## How should income be shared?

| Share | AIIMS IPR Policy 2017 |
|---|---|
| Inventors | 70% |
| Institute | 30% |
| Principal inventor, among several | 50% of the inventor share, unless agreed otherwise |
| With a co-principal investigator | 40% principal inventor, 30% co-PI, 30% others |
| Copyright royalties | 100% to the author |

Generous inventor shares help in a hospital, where clinicians have little time for research administration and need a reason to disclose.

**From bedside idea to licence**
1. Disclose: Before grants, talks or abstracts
2. Committee decides: File, fund, or release
3. Protect: Provisional filing first
4. Control materials: MTA and data agreements
5. License: Through the TTO

## What is different about a hospital?

Three things.

| Issue | Why it matters | What to put in place |
|---|---|---|
| Patient data | Software and diagnostics often rely on patient records | Data protection agreements; ethics committee approval for research use |
| Biological materials | Samples, cell lines and strains leave the lab for collaborators | MTA before any transfer, as AIIMS requires |
| Regulated products | Devices and diagnostics need regulatory approval before sale | Plan validation and test licences with the licensee; see [TRL for medical devices](https://zernyxhub.com/blog/trl-medical-devices) |

Publishing is the other trap. AIIMS's policy prohibits public presentations, abstracts or articles while protection is pending, and allows them after a provisional or complete filing. An abstract submitted before filing can destroy novelty. Ask clinicians to disclose before they submit, and give the cell a fast route to file a provisional when a deadline is close.

## How does ICMR funding change things?

Some medical colleges hold ICMR grants. ICMR's [Technology Transfer and Revenue Sharing Guidelines](https://icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/ICMR_Technology_Transfer_and_Revenue_Sharing_Guidelines07072021.pdf) cover technologies developed with ICMR funding, in-house or extramural:

| Term | ICMR guidelines |
|---|---|
| Default licence | Non-exclusive; exclusive only in exceptional cases with approval |
| Royalty on net sales | Generally 1% to 5%, set by technology readiness |
| Foreign sales | Additional 1% to 2% |
| Sub-licensing | 10% of sub-licensing fees |
| Late payment | 12% simple interest a year |
| Grant recipients | The principal investigator signs an undertaking on revenue sharing |

If an invention came from an ICMR-funded project, check these terms before the college offers a licence. [How a TTO prices a technology](https://zernyxhub.com/blog/tto-technology-pricing) covers the pricing side.

**College-funded or ICMR-funded invention**
College-funded:
- College policy applies
- College decides exclusivity
- Income shared under its policy
ICMR-funded:
- ICMR guidelines apply
- Non-exclusive by default
- PI undertaking on revenue
Check the funding source on every disclosure before you promise terms.

## Who should sit on the committee?

Medical college committees need clinical, scientific, legal and financial views, and each member should know what they are there to judge. AIIMS's IP Management Committee is chaired by the Dean (Research), with the Sub-Dean (Research) as co-chair, four active researchers nominated by the Director (one with a legal background), and the Accounts Officer and Administrative Officer of the Research Section as ex-officio members.

| Role | Why it is needed |
|---|---|
| Senior research leader as chair | Authority to decide and to fund filings |
| Active clinician researchers | Judge clinical value and feasibility |
| Someone with legal background | Agreements, MTAs, data terms |
| Finance officer | Budgets and income handling |
| Member secretary from the IPR cell | Prepares cases and keeps records |

Smaller colleges can combine roles, but should keep at least one member who understands devices or diagnostics and one who can read a contract. AIIMS's policy also lets inventors file in AIIMS's name at their own cost with committee approval, and be reimbursed later, which keeps urgent filings moving when the budget is tight.

## A first-year plan

**Illustration with invented figures.** A 1,000-bed government medical college sets up an IPR cell.

| Item | Year 1 cost |
|---|---|
| IPR officer, full time | ₹9,00,000 |
| Part-time legal support for agreements | ₹3,00,000 |
| Patent filings, about 8 provisionals and 4 complete specifications | ₹6,00,000 |
| Awareness sessions in 20 departments | ₹50,000 |
| Templates: NDA, MTA, data agreement, licence | ₹1,00,000 |
| Total | ₹19,50,000 |

By the end of the year the cell has 25 disclosures, 12 filings and 4 MTAs, and has stopped two abstracts from going out before filing. Licensing income will lag by several years; the first-year measure is disclosures and avoided losses.

## Common mistakes

- No rule on abstracts and conference talks before filing.
- Letting samples and data leave without MTAs or data agreements.
- Ignoring the funding source and its licensing rules.
- Expecting income in year one.
- A committee with no member who understands devices or diagnostics.

My view: in a medical college, the disclosure habit matters more than the size of the cell, because clinicians generate ideas constantly and lose them to early publication. I am less certain how best to give clinicians research time for development work, which varies widely between institutions; a short, protected allocation for promising inventions is worth testing.

Keeping each invention's patent filings and status in one record helps the committee decide quickly. [Zernyx IPMS](https://ipms.zernyxhub.com/) is an IP lifecycle management platform for universities and research institutions, to manage patents, filings and IP portfolios end to end.

## Common questions

### Does a medical college need its own IPR cell?

If its doctors and scientists produce devices, diagnostics, methods or software, yes. Without a cell, inventions are published before anyone files, shared with companies without agreements, or patented privately by individuals. A small cell with a clear policy prevents all three.

### How does AIIMS share licensing income with inventors?

AIIMS's IPR Policy 2017 gives 70% to inventors and 30% to the institute. Among several inventors, the principal inventor receives 50% of the inventor share unless a signed agreement says otherwise. Copyright royalties go entirely to the author.

### What extra rules does a hospital TTO need?

Rules on material transfer agreements before research materials leave the institute, data protection agreements where collaborative research involves sensitive personal data, and compliance with the Biological Diversity Act, 2002 for biological resources. AIIMS's policy covers all three.

### How does ICMR license technologies it funds?

ICMR's technology transfer guidelines make non-exclusive licensing the default for technologies developed with ICMR support, with exclusive licences only in exceptional cases. Royalty on net sales is generally 1% to 5%, set by technology readiness, plus 1% to 2% on foreign sales.

---

Published by Zernyx Hub. More: https://zernyxhub.com/llms.txt
